PSMA Targeted Ligands in Imaging and Theranostics for Prostate Cancer

被引：0
作者：
Sen, Bilge [1 ]
Ozkan, Elgin [2 ]
Kucuk, Nuriye Ozlem [2 ]
机构：
[1] Ankara Univ Inst Hlth Sci, Fac Pharm, Dept Dept Analyt Chem, Ankara, Turkiye
[2] Ankara Univ Fac Med, Deparment Nucl Med, Ankara, Turkiye
来源：
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2023年 / 22卷 / 04期
关键词：
PET imaging; prostate cancer; theranostics; I-AND-T; MEMBRANE ANTIGEN-EXPRESSION; RADIATION-DOSIMETRY; RADIOLIGAND THERAPY; BIOCHEMICAL RECURRENCE; PRECLINICAL EVALUATION; BONE-SCINTIGRAPHY; LYMPH-NODES; PET; BIODISTRIBUTION;
D O I：
10.4274/uob.galenos.2023.2023.8.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prostate cancer (PCa) is the second most common type of cancer in men. Compared with conventional imaging methods, prostate-specific membrane antigen (PSMA)-targeted positron emission tomography has higher accuracy and specificity for the detection and treatment of PCa. Through targeted imaging, ligands are labelled with 18F, 68Ga, or 64Cu, and the disease is staged and managed more accurately. It is also desirable to use PSMA-targeted theranostics that are labelled with either imaging radioisotopes or treatment isotopes such as 177Lu, 225Ac, 131I. Here, we summarized some of the commonly used small molecule PSMA ligands for imaging and theranostic purposes.
引用
收藏
页码：129 / 137
页数：9
相关论文
共 76 条
  • [71] 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
    Werner, Rudolf A.
    Derlin, Thorsten
    Lapa, Constantin
    Sheikbahaei, Sara
    Higuchi, Takahiro
    Giesel, Frederik L.
    Behr, Spencer
    Drzezga, Alexander
    Kimura, Hiroyuki
    Buck, Andreas K.
    Bengel, Frank M.
    Pomper, Martin G.
    Gorin, Michael A.
    Rowe, Steven P.
    [J]. THERANOSTICS, 2020, 10 (01): : 1 - 16
  • [72] Wright G L Jr, 1995, Urol Oncol, V1, P18, DOI 10.1016/1078-1439(95)00002-Y
  • [73] Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
    Wright, GL
    Grob, BM
    Haley, C
    Grossman, K
    Newhall, K
    Petrylak, D
    Troyer, J
    Konchuba, A
    Schellhammer, PF
    Moriarty, R
    [J]. UROLOGY, 1996, 48 (02) : 326 - 334
  • [74] Wurzer A, 2019, J NUCL MED, V60
  • [75] The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax
    Yilmaz, Ugur
    Komek, Halil
    Can, Canan
    Altindag, Serdar
    [J]. ANNALS OF NUCLEAR MEDICINE, 2019, 33 (08) : 545 - 553
  • [76] Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
    Zechmann, Christian M.
    Afshar-Oromieh, Ali
    Armor, Tom
    Stubbs, James B.
    Mier, Walter
    Hadaschik, Boris
    Joyal, John
    Kopka, Klaus
    Debus, Juergen
    Babich, John W.
    Haberkorn, Uwe
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (07) : 1280 - 1292
12345678